Zacks Investment Research on MSN1d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
Nasdaq1mon
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026.
Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug
Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...
Yahoo Finance19d
Novo Nordisk A/S (NOVO-B.CO)
Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial ... results evaluating safety profile and efficacy of Mim8 prophylaxis administered once every two weeks ...
Fox Business15d
Novo Nordisk shares fall on weight-loss drug trial
Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...